Blood Sugar clinical trials

Explore recruiting blood sugar clinical trials.

Recruiting blood sugar studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Blood Sugar trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EFFECT OF ONCE VS TWICE DAILY ADMINISTRATION OF CORTICOSTEROIDS ON BLOOD GLUCOSE IN PATIENTS WITH ANCA-VASCULITIS MEASURED BY CONTINUOUS BLOOD GLUCOSE MONITORING - A PILOT STUDY

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)

Austria, Germany, Poland, Italy, Denmark, Spain +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Protocol Title: Efficacy and safety of once-weekly subcutaneous NNC0662-0419 in participants with type 2 diabetes – a dose-finding study

Spain, Hungary, Portugal, Poland, Slovakia, Croatia

Therapeutic exploratory (Phase II) EU CTIS Study details

PRODIG : Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant period

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Safety and efficacy of once-weekly subcutaneous and once-daily oral NNC0487-0111 in participants with type 2 diabetes – a dose finding study

Romania, Spain, Poland, Slovakia, Hungary, Croatia +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A single arm study investigating the glycaemic control and safety of adding semaglutide to insulin icodec in participants with type 2 diabetes qualifying for treatment intensification.

Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Blood Sugar trials by city

Blood Sugar in Toronto Blood Sugar in Vancouver Blood Sugar in Montreal Blood Sugar in Calgary Blood Sugar in Edmonton Blood Sugar in Ottawa Blood Sugar in Winnipeg Blood Sugar in Quebec City Blood Sugar in Hamilton Blood Sugar in Kitchener Blood Sugar in London Blood Sugar in Halifax Blood Sugar in New York Blood Sugar in Los Angeles Blood Sugar in Chicago Blood Sugar in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease